1. Executive Summary (Confidence: High)

Pureos Bioventures represents the largest institutional Swiss venture capital fund solely dedicated to private biotech companies.^[13] Managed by experienced partners from Bellevue Asset Management, the firm closed its first fund, BB Pureos Bioventures LP, in April 2021 with $205 million in committed capital.^[13] Pureos distinguishes itself through a team of "career venture capitalists" and former biotech founders who have collectively raised hundreds of millions for clinical development and achieved high-value exits.^[15] The firm’s strategy focuses on "Biologicals 2.0"—emerging modalities such as nucleic acids, cell therapies, gene therapies, and next-generation antibody-drug conjugates (ADCs).^[13] With a portfolio that has already produced significant M&A activity (e.g., Ipsen's acquisition of ImCheck and Taiho's acquisition of Araris), Pureos has quickly established itself as a premier gatekeeper for European biotech innovation.^[15]